Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in melanocytes | 0.75 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 204 | 0.82 |
| pathways Reactome | 5 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 0057
Sealed predictions
- MYO5A in oligodendrocytes, braak+0.16 (p 0.312) → -0.12 (p 0.459)receipt 0058
- MYO5A in oligodendrocytes, resilience-0.22 (p 0.391) → -0.19 (p 0.553)receipt 0059
Swarm cases
receipt 0059: MYO5A in oligodendrocytes, resilience
- power
- full sample -0.20 (p 0.313, n 55), 95% CI -0.44 to +0.07. the interval is wide: not enough donors to tell.
- confounder
- adjusted for age, sex and PMI: -0.21 (p 0.293, n 55). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis -0.52 (p 0.0075); controlling for it: -0.05 (p 0.817, n 55). could be the mix.
- skeptic
- leave-one-out range -0.30 to -0.12, sign flips 0; without severely affected donors -0.15 (p 0.463, n 46). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "differs in resilient donors (Lewy pathology, no parkinsonism)" for MYO5A in oligodendrocytes.
case closed: nothing better to follow up.
receipt 0058: MYO5A in oligodendrocytes, braak
- power
- full sample +0.02 (p 0.860, n 84), 95% CI -0.20 to +0.23. the interval sits on zero: probably nothing there.
- confounder
- adjusted for age, sex and PMI: +0.04 (p 0.692, n 84). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.09 (p 0.422); controlling for it: +0.01 (p 0.938, n 84). could be the mix.
- skeptic
- leave-one-out range -0.01 to +0.05, sign flips 5; without severely affected donors -0.07 (p 0.538, n 75). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MYO5A in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts